HSIC Henry Schein
Scale distributor whose price already assumes a margin recovery it hasn't delivered yet; still looks expensive.
The story
Henry Schein is the largest dental and office-based medical distributor in North America and Europe. Its moat is scale, route density and practice-management software lock-in, but it earns thin margins and competes with Patterson, Benco and direct-to-practitioner channels. It is a mature business growing in the low single digits. Margins have been stuck near 5% since the 2023 cyberattack and pricing deflation, and management, with KKR as a backer, is running a cost and value-creation program to move them back toward pre-2022 levels.
TTM revenue of 13.60B is up about 3% on FY 13.18B, so year-1 growth rises to 3.5%. The baseline's -83% gap is far beyond any plausible mispricing for a heavily covered name, so I revisited margin and reinvestment. Target margin moves from 5.8% to 6.5%: that is the 2019-2021 GAAP level, the cost program is underway, and reported margins carry acquisition amortization of about 1.5 points. Sales-to-capital moves from 2.1 to 2.5 (a 19% move) because growth is mostly organic and capex-light; capex of 0.19B is below D&A of 0.30B. Beta moves down slightly to 0.95, close to the industry anchor.
Value drivers
| Revenue growth (Y1) | 3.5% |
| Terminal growth | 2.5% |
| Forecast horizon | 7y |
| Target operating margin | 6.5% |
| Years to target margin | 6 |
| Sales-to-capital | 2.50 |
| Beta | 0.95 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.6% |
| Terminal WACC | 8.8% |
Valuation bridge
| PV of explicit FCFF | 2.66B |
| PV of terminal value | 5.46B |
| Equity value | 2.98B |
| ÷ shares → per share | $26.20 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 14.08B | 3.5% | 5.5% | 586.05M | 190.43M | 395.62M | 364.33M |
| 2 | 14.55B | 3.3% | 5.7% | 628.87M | 187.71M | 441.17M | 374.15M |
| 3 | 15.01B | 3.2% | 5.9% | 672.82M | 184.27M | 488.55M | 381.57M |
| 4 | 15.46B | 3.0% | 6.1% | 717.75M | 180.10M | 537.66M | 386.72M |
| 5 | 15.90B | 2.8% | 6.3% | 763.54M | 175.19M | 588.35M | 389.71M |
| 6 | 16.32B | 2.7% | 6.5% | 810.04M | 169.56M | 640.48M | 390.69M |
| 7 | 16.73B | 2.5% | 6.5% | 830.29M | 163.20M | 667.09M | 374.74M |
Key risks
- Margin recovery stalls because of glove and PPE deflation, mix shift to lower-margin generics, or competitive price pressure from Benco and Amazon Business
- Dental procedure volumes soften in a consumer slowdown, hitting both consumables and equipment
- Leverage (2.95B net debt) and serial bolt-on M&A reduce reinvestment efficiency and add integration or impairment risk
Catalysts
- Delivery on the value-creation plan's non-GAAP margin targets and the high-growth/high-margin segment mix (specialty, technology, own brands)
- Activist or KKR-driven portfolio actions such as divesting medical or monetizing the software segment